Advertisement
Advertisement
NEUP
Neuphoria Therapeutics Inc. Common Stock
4.37
USDSponsored
-0.05
-1.04%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
4.38
+0.01
+0.21%
NEUP Earnings Reports
Positive Surprise Ratio
NEUP beat 1 of 3 last estimates.
33%
Next Report
Date of Next Report
May 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.10
Implied change from Q2 26 (Revenue/ EPS)
--
/+42.86%
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Neuphoria Therapeutics Inc. Common Stock earnings per share and revenue
On Feb 17, 2026, NEUP reported earnings of -0.77 USD per share (EPS) for Q2 26, beating the estimate of -1.49 USD, resulting in a 48.41% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.25% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -1.10 USD, with revenue projected to reach -- USD, implying an increase of 42.86% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Neuphoria Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Neuphoria Therapeutics Inc. Common Stock reported EPS of -$0.77, beating estimates by 48.41%, and revenue of $0.00, 0% as expectations.
How did the market react to Neuphoria Therapeutics Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.25%, changed from $4.05 before the earnings release to $4.06 the day after.
When is Neuphoria Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for May 18, 2026.
What are the forecasts for Neuphoria Therapeutics Inc. Common Stock's next earnings report?
Based on 5
analysts, Neuphoria Therapeutics Inc. Common Stock is expected to report EPS of -$1.10 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement